Literature DB >> 21633404

Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.

Jose M de Miguel-Yanes1, Alisa K Manning, Peter Shrader, Jarred B McAteer, Anuj Goel, Anders Hamsten, Caroline S Fox, Jose C Florez, Josée Dupuis, James B Meigs.   

Abstract

Inhibition of the endocannabinoid receptor CB1 improves insulin sensitivity, lowers glycemia, and slows atherosclerosis. We analyzed whether common variants in the gene encoding CB1, CNR1, are associated with insulin resistance, risk of type 2 diabetes (T2D) or coronary heart disease (CHD). We studied 2,411 participants of the Framingham Offspring Study (mean age 60 years, 52% women) for quantitative traits and CHD, and the Framingham SHARe database for T2D risk. We genotyped 19 single-nucleotide polymorphisms (SNPs) that tagged 85% (at r(2) = 0.8) of common (>5%) CNR1 SNPs. Fasting blood glucose and insulin at the 7th (1999-2001) exam were collected. We used age-, sex-, BMI-adjusted models to test additive associations of genotype with homeostasis model assessment of insulin resistance (HOMA(IR)) (linear mixed-effect models), T2D, or CHD. To account for multiple tests of SNPs, we generated empirical P values. The C allele at SNP rs806365 (frequency, 57.4%), ~4.1 kb 3' from CNR1, was associated with increased HOMA(IR) (n = 2,261, β = 0.05 per C, empirical P = 0.01), risk of T2D (674 cases, odds ratio = 1.19 per C, nominal P = 0.01) and CHD (237 cases, hazard ratio = 1.23 per C, nominal P = 0.04). The association of rs806365 with HOMA(IR) was replicated in a meta-analysis of two independent cohorts (National Health and Nutrition Examination Survey III genetic cohort (NHANES-III) plus Partners Case-Control Diabetes Study; 2,540 white individuals, β = 0.037, nominal P = 0.007), but not in the large Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Consortium (n = 29,248, nominal P = 0.74). The association of rs806365 was not replicated either with T2D in Diabetes Genetics Replication and Meta-analysis (DIAGRAM) (n = 10,128, nominal P = 0.31), or with CHD in PROCARDIS (n = 13,614, nominal P = 0.37). Although supported by initial results, we found no reproducible statistical association of common variation at CNR1 with insulin resistance, T2D, or CHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21633404      PMCID: PMC3686489          DOI: 10.1038/oby.2011.135

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  43 in total

1.  A trio family study showing association of the lymphotoxin-alpha N26 (804A) allele with coronary artery disease.

Authors: 
Journal:  Eur J Hum Genet       Date:  2004-09       Impact factor: 4.246

2.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

3.  Multipoint quantitative-trait linkage analysis in general pedigrees.

Authors:  L Almasy; J Blangero
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

Review 4.  International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.

Authors:  A C Howlett; F Barth; T I Bonner; G Cabral; P Casellas; W A Devane; C C Felder; M Herkenham; K Mackie; B R Martin; R Mechoulam; R G Pertwee
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

5.  Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance--a population-based twin study.

Authors:  P Poulsen; K O Kyvik; A Vaag; H Beck-Nielsen
Journal:  Diabetologia       Date:  1999-02       Impact factor: 10.122

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat.

Authors:  Adam P Chambers; Keith A Sharkey; Henry S Koopmans
Journal:  Physiol Behav       Date:  2004-10-15

8.  Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse.

Authors:  P-W Zhang; H Ishiguro; T Ohtsuki; J Hess; F Carillo; D Walther; E S Onaivi; T Arinami; G R Uhl
Journal:  Mol Psychiatry       Date:  2004-10       Impact factor: 15.992

9.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.

Authors:  C Ravinet Trillou; C Delgorge; C Menet; M Arnone; P Soubrié
Journal:  Int J Obes Relat Metab Disord       Date:  2004-04

10.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

View more
  7 in total

1.  Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity.

Authors:  Tina K Thethi; Aster Sigel; Shanker Japa; Bonnie Katalenich; Shuqian Liu; Tuyen Nguyen; Joshua Larrazolo; Stephanie Syu; Esther Carefoot; Roberta McDuffie; Vivian Fonseca
Journal:  J Diabetes Complications       Date:  2020-07-17       Impact factor: 2.852

2.  A common functional promoter variant links CNR1 gene expression to HDL cholesterol level.

Authors:  Q Feng; K C Vickers; M P Anderson; M G Levin; W Chen; D G Harrison; R A Wilke
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans.

Authors:  Douglas R Smith; Christine M Stanley; Theodore Foss; Richard G Boles; Kevin McKernan
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

4.  Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders.

Authors:  Kathryn J Lester; Jonathan R I Coleman; Susanna Roberts; Robert Keers; Gerome Breen; Susan Bögels; Cathy Creswell; Jennifer L Hudson; Anna McKinnon; Maaike Nauta; Ronald M Rapee; Silvia Schneider; Wendy K Silverman; Mikael Thastum; Polly Waite; Gro Janne H Wergeland; Thalia C Eley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-06-27       Impact factor: 3.568

Review 5.  The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.

Authors:  F Hosseinkhani; A Heinken; I Thiele; P W Lindenburg; A C Harms; T Hankemeier
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 6.  What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?

Authors:  Piotr Schulz; Szymon Hryhorowicz; Anna Maria Rychter; Agnieszka Zawada; Ryszard Słomski; Agnieszka Dobrowolska; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2021-01-26       Impact factor: 5.717

Review 7.  Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.

Authors:  Yulia A Nasykhova; Ziravard N Tonyan; Anastasiia A Mikhailova; Maria M Danilova; Andrey S Glotov
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.